LadRx Corporation (CYTR) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
LadRx Corporation (CYTR) trades at $0.09. LadRx Corporation (CYTR) is a biopharmaceutical company focused on developing cancer therapeutics. Their lead drug conjugate, aldoxorubicin, is in late-stage clinical trials, targeting a version of the anti-cancer drug doxorubicin. Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for CYTR: CYTR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CYTR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CYTR: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bullish.
How is this calculated? →LadRx Corporation (CYTR) Healthcare & Pipeline Overview
LadRx Corporation, a biopharmaceutical firm, specializes in cancer therapeutics, with its lead drug aldoxorubicin in late-stage trials. Formerly CytRx, the company focuses on linker-activated drug releases, operating in a competitive biotech landscape while navigating the complexities of OTC markets and limited resources.
What Is the Investment Thesis for CYTR?
LadRx Corporation presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is significantly influenced by the progress of aldoxorubicin through late-stage clinical trials. Positive trial results could lead to substantial gains, while failure could severely impact the company's prospects. Key value drivers include successful completion of clinical trials, regulatory approvals, and potential partnerships for commercialization. The company's negative P/E ratio of -0.02 and a profit margin of -17519.8% highlight its current lack of profitability, making it reliant on external funding. The company's beta of 2.10 indicates high volatility relative to the market. The stock's OTC listing adds further risk due to lower liquidity and transparency.
Based on FMP financials and quantitative analysis
CYTR Key Highlights
P/E ratio of -0.02, reflecting the company's current lack of profitability.
- Profit Margin of -17519.8%, indicating significant losses relative to revenue.
- Gross Margin of 24.0%, showing the percentage of revenue exceeding the cost of goods sold.
- Beta of 2.10, suggesting the stock is more volatile than the overall market.
- The company's focus on aldoxorubicin, a late-stage clinical trial drug, represents a potential high-reward opportunity.
Who Are CYTR's Competitors?
CYTR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BRRGF BerGenBio ASA | $97.09 | +0.00% | $9.49B | 74 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
| NBIX Neurocrine Biosciences, Inc. | $153.42 | -1.37% | $15.4B | 93 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CYTR's Key Strengths?
Late-stage clinical trial drug (aldoxorubicin).
- Proprietary drug conjugate technology.
- Experienced management team.
- Focus on a high-need area (cancer therapeutics).
What Are CYTR's Weaknesses?
Limited financial resources.
- Small number of employees.
- Dependence on the success of aldoxorubicin.
- OTC market listing.
What Could Drive CYTR Stock Higher?
Publication of results from ongoing aldoxorubicin clinical trials (2026-2027).
- Potential FDA/EMA regulatory submissions for aldoxorubicin (2027-2028).
- Strategic partnerships and collaborations with pharmaceutical companies.
- Securing additional funding through grants or equity offerings.
What Are the Key Risks for CYTR?
Clinical trial failures for aldoxorubicin.
- Regulatory hurdles and delays in obtaining approvals.
- Competition from larger pharmaceutical companies with greater resources.
- Dependence on external funding to support operations.
- Risks associated with OTC market listing, including limited liquidity and transparency.
What Are the Growth Opportunities for CYTR?
- Successful Completion of Aldoxorubicin Clinical Trials: The successful completion of late-stage clinical trials for aldoxorubicin represents a significant growth opportunity for LadRx Corporation. Positive results could lead to regulatory approval and commercialization, potentially generating substantial revenue. The market for cancer therapeutics is estimated to reach $200 billion by 2026, providing a large addressable market for aldoxorubicin. Timeline: 2026-2028.
- Expansion of Pre-Clinical Pipeline: LadRx's pre-clinical therapeutics, including linker-activated drug releases 7, 8, 9, and 10, offer potential for future growth. Advancing these programs through pre-clinical and clinical development could lead to new drug candidates and expanded market opportunities. The market for targeted drug delivery systems is projected to grow to $80 billion by 2027. Timeline: 2027-2030.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies could provide LadRx with access to funding, expertise, and resources needed to accelerate drug development and commercialization. Collaborations can also help expand the company's reach and market presence. The value of pharmaceutical collaborations is expected to reach $150 billion by 2028. Timeline: Ongoing.
- Securing Additional Funding: LadRx's ability to secure additional funding through grants, equity offerings, or debt financing is crucial for supporting its research and development activities. Adequate funding is essential for advancing clinical trials and expanding the company's pipeline. The availability of venture capital for biotechnology companies is projected to remain strong through 2026. Timeline: Ongoing.
- Regulatory Approvals and Market Access: Obtaining regulatory approvals from agencies such as the FDA in the United States and the EMA in Europe is essential for commercializing LadRx's drug candidates. Successful market access strategies are also needed to ensure that the company's products are available to patients. The market for oncology drugs is heavily regulated, requiring compliance with stringent safety and efficacy standards. Timeline: 2027-2029.
What Are CYTR's Competitive Advantages?
- Proprietary drug conjugates with potential for improved efficacy and reduced toxicity.
- Late-stage clinical trial drug (aldoxorubicin) provides a competitive advantage.
- Intellectual property protection for its drug candidates.
- Experienced management team with expertise in drug development.
What Does CYTR Do?
LadRx Corporation, formerly known as CytRx Corporation, was founded in 1985 and rebranded in September 2022. Headquartered in Los Angeles, California, the company is dedicated to discovering and developing innovative therapeutics for cancer treatment. LadRx's primary focus is on aldoxorubicin, an advanced drug conjugate currently undergoing late-stage clinical trials. Aldoxorubicin represents a modified version of doxorubicin, a well-established anti-cancer drug, designed to improve efficacy and reduce toxicity. In addition to aldoxorubicin, LadRx is also developing a range of pre-clinical therapeutics, including linker-activated drug releases 7, 8, 9, and 10, all targeted against various forms of cancer. These early-stage programs aim to leverage novel drug delivery mechanisms to enhance therapeutic outcomes. The company operates within the highly competitive biotechnology sector, facing challenges related to funding, regulatory approvals, and clinical trial success. With a small team of three employees, LadRx navigates the complexities of drug development while striving to bring new treatment options to cancer patients.
What Products and Services Does CYTR Offer?
- Develops therapeutics for cancer treatment.
- Focuses on aldoxorubicin, a drug conjugate in late-stage clinical trials.
- Creates linker-activated drug releases targeting cancer.
- Conducts pre-clinical research to discover new drug candidates.
- Aims to improve the efficacy and reduce the toxicity of existing anti-cancer drugs.
- Seeks regulatory approvals for its drug candidates.
How Does CYTR Make Money?
- Develop and license novel cancer therapeutics.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from agencies like the FDA.
- Commercialize approved drugs through partnerships or direct sales.
What Industry Does CYTR Operate In?
LadRx Corporation operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential. The industry is driven by innovation and the constant search for new and improved therapies. LadRx's focus on cancer therapeutics aligns with the growing global demand for effective cancer treatments. Competitors include companies like BRRGF (Barrick Gold Corp), DOGP (Dogness Corp), FTHWF (Future Health Wellness), GHSI (Guardion Health Sciences Inc), and IPCIF (IC Potash Corp), each pursuing different approaches to healthcare and biotechnology. The company's success depends on its ability to navigate the complex regulatory landscape and secure funding to advance its clinical programs.
Who Are CYTR's Key Customers?
- Cancer patients in need of new treatment options.
- Oncologists and other healthcare professionals.
- Hospitals and cancer treatment centers.
- Pharmaceutical companies interested in licensing or acquiring new drugs.
Company Profile
LadRx Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Los Angeles, US. The company is led by CEO Steven Kriegsman. CYTR has traded publicly since 1986.
Key Financial Metrics
Return on equity for LadRx Corporation stands at 21.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.11 means current liabilities exceed short-term assets, a liquidity point worth watching.
Insider Activity
The most recent 9 insider filings for LadRx Corporation break down as 3 sales and 6 purchases. On net that is roughly 89K shares disposed (about $383K), a signal worth weighing alongside the fundamentals.
CYTR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Late-stage clinical trial drug (aldoxorubicin).
- Proprietary drug conjugate technology.
- Experienced management team.
- Focus on a high-need area (cancer therapeutics).
Bear Case
- Limited financial resources.
- Small number of employees.
- Dependence on the success of aldoxorubicin.
- OTC market listing.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
CYTR Latest News
-
Stocks That Hit 52-Week Lows On Friday
· Aug 16, 2019
CYTR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CYTR.
Price Targets
Wall Street price target analysis for CYTR.
CYTR MoonshotScore
What does this score mean?
The MoonshotScore rates CYTR 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Steven Kriegsman
CEO
Steven Kriegsman serves as the CEO of LadRx Corporation, managing a small team of three employees. His background includes experience in the biotechnology and pharmaceutical industries, with a focus on drug development and commercialization. Kriegsman has held various leadership positions in both public and private companies, contributing to strategic planning, fundraising, and operational execution. He brings a wealth of knowledge in navigating the complexities of the healthcare sector.
Track Record: Under Steven Kriegsman's leadership, LadRx Corporation has focused on advancing aldoxorubicin through late-stage clinical trials. Key milestones include securing funding for clinical development, achieving positive clinical trial results, and rebranding the company to LadRx Corporation. Kriegsman has also overseen the expansion of the company's pre-clinical pipeline and the exploration of strategic partnerships.
CYTR OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that LadRx Corporation may not meet the minimum financial or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and performance. Investing in OTC Other stocks carries higher risks due to the potential for fraud, manipulation, and lack of liquidity. These companies may not be required to adhere to the same regulatory standards as those listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure due to OTC Other tier status.
- Lower liquidity and wider bid-ask spreads.
- Increased price volatility.
- Potential for fraud and manipulation.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's clinical trial data and regulatory prospects.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any legal or regulatory actions against the company.
- Focus on cancer therapeutics, addressing a significant medical need.
- Late-stage clinical trial drug (aldoxorubicin).
- Experienced management team with expertise in drug development.
- History as a publicly traded company (formerly CytRx Corporation).
CYTR Healthcare Stock FAQ
What does LadRx Corporation do?
LadRx Corporation is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for cancer treatment. Its lead drug candidate, aldoxorubicin, is in late-stage clinical trials and aims to improve the efficacy and reduce the toxicity of the anti-cancer drug doxorubicin. The company also has a pipeline of pre-clinical therapeutics targeting various forms of cancer.
What do analysts say about CYTR stock?
As of March 17, 2026, there is no readily available analyst coverage for LadRx Corporation (CYTR) due to its OTC listing and small market capitalization. Key valuation metrics such as price targets and earnings estimates are not widely tracked. Investors should conduct their own thorough research and consider the risks associated with investing in OTC stocks.
What are the main risks for CYTR?
The main risks for LadRx Corporation include clinical trial failures, regulatory hurdles, competition from larger pharmaceutical companies, and dependence on external funding. Clinical trial failures could significantly impact the company's prospects and valuation. Regulatory delays or denials could also hinder the commercialization of its drug candidates.
What are the key factors to evaluate for CYTR?
Evaluate CYTR on fundamentals, analyst consensus, and risk factors. LadRx Corporation presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does CYTR data refresh on this page?
CYTR's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CYTR's recent stock price performance?
LadRx Corporation (CYTR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Late-stage clinical trial drug (aldoxorubicin). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CYTR overvalued or undervalued right now?
LadRx Corporation (CYTR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CYTR before investing?
Before investing in LadRx Corporation (CYTR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available due to OTC listing and small market capitalization.
- AI analysis pending for CYTR, which may provide further insights.